ARROW ELECTRONICS, INC.
Exhibit 1.1
$300,000,000
ARROW ELECTRONICS, INC.
6.000% NOTES DUE 2020
September 23, 2009
September 23, 0000
Xxxx xx Xxxxxxx Securities LLC
Xxxxxxx, Xxxxx & Co.
X.X. Xxxxxx Securities Inc.
As Representatives of the several underwriters named in Schedule I
c/o X.X. Xxxxxx Securities Inc.
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Xxxxxxx, Xxxxx & Co.
X.X. Xxxxxx Securities Inc.
As Representatives of the several underwriters named in Schedule I
c/o X.X. Xxxxxx Securities Inc.
000 Xxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Dear Sirs and Mesdames:
Arrow Electronics, Inc., a New York corporation (the “Company”), proposes to issue and sell to
the several underwriters named in Schedule I hereto (the “Underwriters”) $300,000,000
aggregate principal amount of its 6.000% Notes due 2020 (the “Securities”), the terms of which are
identified on Schedule III hereto, to be issued pursuant to the provisions of an Indenture
dated as of January 15, 1997, as supplemented (the “Indenture”) between the Company and Bank of New
York Mellon (as successor to Bank of Montreal Trust Company), as Trustee (the “Trustee”).
The Company has filed with the Securities and Exchange Commission (the “Commission”) a
registration statement on Form S-3, including a prospectus, relating to among other things, certain
debt securities and equity securities of the Company (the “Shelf Securities”), including the
Securities, to be issued from time to time by the Company. The registration statement as amended
to the date of this Agreement, including the information (if any) deemed to be part of the
registration statement at the time of effectiveness pursuant to Rule 430A or Rule 430B under the
Securities Act of 1933, as amended (the “Securities Act”), is hereinafter referred to as the
“Registration Statement,” and the related prospectus covering the Shelf Securities dated September
23, 2009, in the form first used to confirm sales of the Securities (or in the form first made
available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173
under the Securities Act) is hereinafter referred to as the “Basic Prospectus.” The Basic
Prospectus, as supplemented by the prospectus supplement specifically relating to the Securities in
the form first used to confirm sales of the Securities (or in the form first made available to the
Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the
Securities Act) is hereinafter referred to as the “Prospectus,” and the term “preliminary
prospectus” means any preliminary form of the Prospectus. For purposes of this Agreement, “free
writing prospectus” has the meaning set forth in Rule 405 under the Securities Act, and “Time of
Sale Prospectus” means the Basic Prospectus, as supplemented by the preliminary prospectus
supplement dated September 23, 2009, specifically relating to the Securities in the form made
available to the Underwriters by the Company together with the free writing prospectuses, if any,
each identified on Schedule II hereto. As used herein, the terms “Registration Statement,”
“Basic Prospectus,” “Prospectus,” “preliminary prospectus” and “Time of Sale Prospectus” shall
include in each case the documents, if any, incorporated by reference therein. The term “Time of
Sale” shall mean 3:40 p.m. (Eastern time) on September 23, 2009, which is the time of the first
contract of sale for the Securities. The terms “supplement,” “amendment” and “amend” as used
herein with respect
1
to the Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any
preliminary prospectus or free writing prospectus shall include all documents subsequently filed by
the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), that are deemed to be incorporated by reference therein.
1. Representations and Warranties. The Company represents and warrants to and agrees with
each of the Underwriters that:
(a) The Registration Statement has become effective; no stop order suspending the
effectiveness of the Registration Statement is in effect, and no proceedings for such
purpose are pending before or threatened by the Commission. If the Registration Statement
is an automatic shelf registration statement as defined in Rule 405 under the Securities
Act, the Company is a well-known seasoned issuer (as defined in Rule 405 under the
Securities Act) eligible to use the Registration Statement as an automatic shelf
registration statement and the Company has not received notice that the Commission objects
to the use of the Registration Statement as an automatic shelf registration statement.
(b) (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and
incorporated by reference in the Time of Sale Prospectus or the Prospectus complied or will
comply when so filed in all material respects with the Exchange Act and the applicable rules
and regulations of the Commission thereunder, (ii) the Registration Statement does not
contain, each part of the Registration Statement, when such part became effective, did not
contain, and each such part, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, (iii) the Registration
Statement and the Prospectus comply, and as amended or supplemented, if applicable, will
comply in all material respects with the Securities Act and the applicable rules and
regulations of the Commission thereunder, (iv) the Time of Sale Prospectus does not, and at
the time of each sale of the Securities in connection with the offering when the Prospectus
is not yet available to prospective purchasers and at the Closing Date (as defined in
Section 4), the Time of Sale Prospectus, as then amended or supplemented, if applicable,
will not, contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, and (v) the Prospectus does not contain and, as amended or
supplemented, if applicable, will not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, except that the representations
and warranties set forth in this paragraph do not apply to (A) statements or omissions in
the Registration Statement, the Time of Sale Prospectus or the Prospectus made in reliance
upon and in conformity with information furnished to the Company in writing by such
Underwriter through you expressly for use therein or (B) that part of the Registration
Statement that constitutes the Statement of Eligibility (Form T-1) under the Trust Indenture
Act of 1939, as amended (the “Trust Indenture Act”), of the Trustee.
2
(c) The Company is not an “ineligible issuer” in connection with the offering pursuant
to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the
Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or
will be, filed with the Commission in accordance with the requirements of the Securities Act
and the applicable rules and regulations of the Commission thereunder. Each free writing
prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the
Company complies or will comply in all material respects with the requirements of the
Securities Act and the applicable rules and regulations of the Commission thereunder.
Except for the free writing prospectuses, if any, identified in Schedule II hereto,
each furnished to you before first use, the Company has not prepared, used or referred to,
and will not, without your prior consent, prepare, use or refer to, any free writing
prospectus.
(d) Since the respective dates as of which information is given in the Time of Sale
Prospectus, there has not been any material adverse change, or any development involving a
prospective material adverse change, in or affecting the general affairs, management,
financial position, or results of operations of the Company and its Material Subsidiaries
(as defined below), otherwise than as set forth or contemplated in the Time of Sale
Prospectus and the Prospectus.
(e) The Company has been duly incorporated and is validly existing as a corporation in
good standing under the laws of the State of New York, with power and authority (corporate
and other) to own its properties and conduct its business as described in the Time of Sale
Prospectus and the Prospectus, and has been duly qualified as a foreign corporation for the
transaction of business and is in good standing under the laws of each other jurisdiction in
which the conduct of its business or its ownership or leasing of property requires such
qualification, except to the extent that the failure to be so qualified or be in good
standing would not have a material adverse effect on the Company and its subsidiaries, taken
as a whole; and each subsidiary of the Company which constitutes a “significant subsidiary”
within the meaning of Rule 1-02 of Regulation S-X and each subsidiary of the Company which
constitutes a “restricted subsidiary” within the meaning of the Indenture (together, the
“Material Subsidiaries”), has been duly incorporated and is validly existing as a
corporation in good standing under the laws of its jurisdiction of incorporation, with power
and authority (corporate and other) to own its properties and to conduct its business as
described in the Time of Sale Prospectus, and has been duly qualified as a foreign
corporation for the transaction of business and is in good standing under the laws of each
other jurisdiction in which the conduct of its business or its ownership or leasing of
property requires such qualification, except to the extent that the failure to be so
qualified or be in good standing would not have a material adverse effect on the Company and
its subsidiaries, taken as a whole.
(f) This Agreement has been duly authorized, executed and delivered by the Company; the
Securities have been duly authorized and, when issued and delivered pursuant to this
Agreement, will have been duly executed, authenticated, issued and delivered and will
constitute valid and legally binding obligations of the Company entitled to the benefits
provided by the Indenture, under which they are to be issued,
3
which will be substantially in the form previously delivered to you; the Indenture has
been duly qualified under the Trust Indenture Act and has been duly authorized, executed and
delivered by the Company and constitutes a valid and legally binding instrument, enforceable
in accordance with its terms, subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other laws of general applicability relating to or affecting creditors’
rights and to general equity principles; and the Securities and the Indenture will conform
to the descriptions thereof in the Time of Sale Prospectus and the Prospectus and will be in
substantially the form previously delivered to you.
(g) Each preliminary prospectus filed as part of the registration statement as
originally filed or as part of any amendment thereto, or filed pursuant to Rule 424 under
the Securities Act, complied when so filed in all material respects with the Securities Act
and the applicable rules and regulations of the Commission thereunder.
(h) Prior to the date hereof, neither the Company nor any of its affiliates has taken
any action which is designed to or which has constituted or which might have been expected
to cause or result in stabilization or manipulation of the price of any security of the
Company in connection with the offering of the Securities.
(i) The execution and delivery by the Company of, and the performance by the Company of
its obligations under, this Agreement, the Indenture and the Securities will not contravene
any provision of applicable law or the certificate of incorporation or by-laws of the
Company or any agreement or other instrument binding upon the Company or any of its Material
Subsidiaries or to which any of its or their properties are subject that is material to the
Company and its subsidiaries, taken as a whole, or any material judgment, order or decree of
any governmental body, agency or court having jurisdiction over the Company or any Material
Subsidiary or any of their properties, and no consent, approval, authorization or order of,
or qualification with, any governmental body or agency is required for the performance by
the Company of its obligations under this Agreement, the Indenture and the Securities,
except such as may be required by the securities or Blue Sky laws of the various states in
connection with the offer and sale of the Securities.
(j) Other than as set forth in the Time of Sale Prospectus and the Prospectus, there
are no legal or governmental proceedings pending to which the Company or any of its
subsidiaries is a party or of which any property of the Company or any of its subsidiaries
is the subject which, if determined adversely to the Company or any of its subsidiaries,
would individually or in the aggregate have a material adverse effect on the Company and its
subsidiaries, taken as a whole, and, to the best of the Company’s knowledge, no such
proceedings are threatened or contemplated by governmental authorities or threatened by
others.
(k) The Company is not, and after giving effect to the offering and sale of the
Securities, will not be an “investment company”, as such term is defined in the United
States Investment Company Act of 1940, as amended (the “Investment Company Act”).
4
(l) The Company and its Material Subsidiaries (i) are in compliance with any and all
applicable foreign, federal, state and local laws and regulations relating to the protection
of human health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses
or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses and (iii) are in compliance with all terms and conditions of any such
permit, license or approval, except where such noncompliance with Environmental Laws,
failure to receive required permits, licenses or other approvals or failure to comply with
the terms and conditions of such permits, licenses or approvals would not, singly or in the
aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a
whole.
(m) Ernst & Young LLP, who has certified certain financial statements of the Company
and its subsidiaries is an independent public accountant as required by the Securities Act
and the rules and regulations of the Commission thereunder.
(n) The operations of the Company and its subsidiaries are and have been conducted in
all material respects at all times in compliance with applicable financial recordkeeping and
reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no
action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any of its subsidiaries with respect to the Money
Laundering Laws is pending or, to the best knowledge of the Company, threatened.
(o) None of the Company, any of its subsidiaries or, to the knowledge of the Company,
any director, officer, agent, employee or affiliate of the Company or any of its
subsidiaries is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”); and the Company will
not directly or indirectly use the proceeds of the offering hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.
2. Agreements to Sell and Purchase. Subject to the terms and conditions herein set forth,
the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters
agrees, severally and not jointly, to purchase from the Company, at a purchase price of 99.319% of
the aggregate principal amount thereof (the “Purchase Price”) with respect to the Securities plus
accrued interest, if any, to the Closing Date, the principal amount of Securities set forth
opposite the name of such Underwriter in Schedule I hereto.
3. Terms of Public Offering. (a) The Company is advised by you that the Underwriters
propose to make a public offering of their respective portions of the Securities as soon after the
parties have executed this Agreement as in your judgment is advisable. The Company is further
advised by you that the Securities are to be offered to the public initially at
99.969% of their principal amount (the “Public Offering Price”) plus accrued interest, if
any, to the Closing Date.
5
(b) Each Underwriter severally represents and warrants to and agrees with the Company
that:
(1) in relation to each member state of the European Economic Area that has
implemented the Prospectus Directive (each, a relevant member state), each
Underwriter has represented and agreed that with effect from and including the date
on which the Prospectus Directive is implemented in that relevant member state (the
relevant implementation date), it has not made and will not make an offer of the
Securities to the public in that relevant member state other than: (i) at any time
to any legal entity that is authorized or regulated to operate in the financial
markets or, if not so authorized or regulated, whose corporate purpose is solely to
invest in securities; (ii) at any time to any legal entity that has two or more of
(A) an average of at least 250 employees during the last financial year; (B) a total
balance sheet of more than €43,000,000 and (C) an annual net turnover of more than
€50,000,000, as shown in its last annual or consolidated accounts; (iii) to fewer
than 100 natural or legal persons (other than qualified investors defined in the
Prospectus Directive) subject to obtaining the prior written consent of the
representatives or (iv) at any time in any other circumstances that do not require
the publication of a prospectus pursuant to Article 3 of the Prospectus Directive;
provided that no such offer of Securities referred to in (i) to (iii) above shall
require the Company or any Underwriter to publish a prospectus pursuant to Article 3
of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the
Prospectus Directive. For purposes of this provision, the expression an “offer of
securities to the public” in any relevant member state means the communication in
any form and by any means of sufficient information on the terms of the offer and
the securities to be offered so as to enable an investor to decide to purchase or
subscribe the securities, as the expression may be varied in that member state by
any measure implementing the Prospectus Directive in that member state, and the
expression “Prospectus Directive” means Directive 003/71/EC and includes any
relevant implementing measure in each relevant member state;
(2) (i) it has only communicated or caused to be communicated and will only
communicate or cause to be communicated an invitation or inducement to engage in
investment activity (within the meaning of Section 21 of the Financial Services and
Markets Xxx 0000 (the “FSMA”) received by it in connection with the issue or sale of
the Securities in circumstances in which Section 21(1) of the FSMA does not apply to
the Company; and (ii) it has complied and will comply with all applicable provisions
of the FSMA with respect to anything done by it in relation to the Securities in,
from or otherwise involving the United Kingdom;
(3) it has not offered or sold and will not make an offer or sell the
Securities by means of any document other than (i) in circumstances which do not
6
constitute an offer to the public within the meaning of the Companies Ordinance
(Cap.32, Laws of Hong Kong), or (ii) to “professional investors” within the meaning
of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules
made thereunder, or (iii) in other circumstances which do not result in the document
being a “prospectus” within the meaning of the Companies Ordinance (Cap.32, Laws of
Hong Kong), and no advertisement, invitation or document relating to the notes may
be issued or may be in the possession of any person for the purpose of issue (in
each case whether in Hong Kong or elsewhere), which is directed at, or the contents
of which are likely to be accessed or read by, the public in Hong Kong (except if
permitted to do so under the laws of Hong Kong) other than with respect to
Securities which are or are intended to be disposed of only to persons outside Hong
Kong or only to “professional investors” within the meaning of the Securities and
Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder;
(4) the Securities have not been registered under the Securities and Exchange
Law of Japan (the “Securities and Exchange Law”), and it has not offered or sold and
it will not offer or sell any Securities, directly or indirectly, in Japan or to, or
for the benefit of, any resident of Japan (which term as used herein means any
person resident in Japan, including any corporation or other entity organized under
the laws of Japan), or to others for re-offering or resale, directly or indirectly,
in Japan or to a resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with, the Securities and
Exchange Law and any other applicable laws, regulations and ministerial guidelines
of Japan; and
(5) the Prospectus has not been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, the Prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or
purchase, of the Securities may not be circulated or distributed, nor may the
Securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore
other than (i) to an institutional investor under Section 274 of the Securities and
Futures Act, Chapter 289 of Singapore (the “SFA”), (ii) to a relevant person, or any
person pursuant to Section 275(1A), and in accordance with the conditions, specified
in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA.
4. Payment and Delivery. (a) The Securities to be purchased severally by each Underwriter
hereunder, registered in the name of Cede & Co. as nominee of The Depository Trust Company
(“DTC”), shall be delivered through the facilities of DTC by or on behalf of the Company to you,
for the account of such Underwriter, against payment by or on behalf of such Underwriter of the
purchase price therefor by wire transfer to an account designated by the Company, payable to the
order of the Company in Federal (same-day) funds. The time and date of such delivery and payment
shall be 9:30 a.m., New York City time, on September 30, 2009
or such other time and date as you and the Company may agree upon in writing. Such time and
date are herein called the “Closing Date”.
7
(b) The documents to be delivered at the Closing Date by or on behalf of the parties
hereto pursuant to Section 6 hereof, including the cross-receipt for the Securities and any
additional documents requested by the Underwriters pursuant to Section 6 hereof, will be
delivered at the offices of Milbank, Tweed, Xxxxxx & XxXxxx LLP, 0 Xxxxx Xxxxxxxxx Xxxxx,
Xxx Xxxx, XX 00000 (the “Closing Location”) on the Closing Date. A meeting will be held at
the Closing Location at 9:30 a.m., New York City time, on the New York Business Day next
preceding the Closing Date, at which meeting the final drafts of the documents to be
delivered pursuant to the preceding sentence will be available for review by the parties
hereto. For the purposes of this Section 4, “New York Business Day” shall mean each Monday,
Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in
New York are generally authorized or obligated by law or executive order to close.
5. Covenants of the Company. The Company covenants with each Underwriter as follows:
(a) To prepare the Registration Statement, the Time of Sale Prospectus and the
Prospectus in a form approved by you and, before amending or supplementing the Registration
Statement, the Time of Sale Prospectus or the Prospectus, to furnish to the Underwriters a
copy of each such proposed amendment or supplement and not to use any such proposed
amendment or supplement to which the Underwriters reasonably object, and to file with the
Commission within the applicable period specified in Rule 424(b) under the Securities Act,
any prospectus required to be filed pursuant to such Rule.
(b) To endeavor to qualify the Securities for offer and sale under the securities or
Blue Sky laws of such jurisdictions as you shall reasonably request and to maintain such
qualification for as long as you shall reasonably request.
(c) To furnish to you a copy of each proposed free writing prospectus to be prepared by
or on behalf of, used by, or referred to by the Company and not to use or refer to any
proposed free writing prospectus to which you reasonably object.
(d) If the Time of Sale Prospectus is being used to solicit offers to buy the
Securities at a time when the Prospectus is not yet available to prospective purchasers and
any event shall occur or condition exist as a result of which it is necessary to amend or
supplement the Time of Sale Prospectus in order to make the statements therein, in the light
of the circumstances, not misleading, or if any event shall occur or condition exist as a
result of which the Time of Sale Prospectus conflicts with the information contained in the
Registration Statement then on file, or if, in the opinion of counsel for the Underwriters,
it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable
law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the
Underwriters and to any dealer upon request, either amendments or supplements to the Time of
Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or
supplemented will not, in the light of the
8
circumstances when the Time of Sale Prospectus is delivered to a prospective purchaser,
be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no
longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as
amended or supplemented, will comply with applicable law.
(e) To furnish you with copies of the Registration Statement, each amendment or
supplement thereto signed by an authorized officer of the Company (including exhibits
thereto and documents incorporated therein by reference), and to each of the Underwriters
the Time of Sale Prospectus, the Prospectus and any documents incorporated therein by
reference, in each case in such quantities as you may from time to time reasonably request,
and if, during such period after the first date of the public offering of the Securities as
in the opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice
referred to in Rule 173(a) under the Securities Act) is required by law to be delivered in
connection with sales by an Underwriter or a dealer, any event shall have occurred as a
result of which the Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state any material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made when
such Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the
Securities Act) is delivered, not misleading, or if, in the opinion of counsel for the
Underwriters, it shall be necessary during such same period to amend or supplement the
Prospectus to comply with applicable law, to notify you and upon your request to prepare and
furnish without charge to each Underwriter and to any dealer in securities as many copies as
you may from time to time reasonably request of an amended Prospectus or a supplement to the
Prospectus which will correct such statement or omission or effect such compliance.
(f) Not to be or become, at any time prior to the earlier of (i) the expiration of
three years after the Closing Date or (ii) the time when there are no longer any Securities
outstanding, an open-end investment company, unit investment trust, closed-end investment
company or face-amount certificate company that is or is required to be registered under
Section 8 of the Investment Company Act.
(g) Whether or not the transactions contemplated in this Agreement are consummated or
this Agreement is terminated, to pay or cause to be paid the following: (i) the fees,
disbursements and expenses of the Company’s counsel and accountants in connection with the
registration and delivery of the Securities under the Securities Act and all other expenses
in connection with the preparation, printing and filing of the Registration Statement, any
preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any free writing
prospectus prepared by or on behalf of, used by, or referred to by the Company, and any
amendments and supplements to any of the foregoing and the mailing and delivering of copies
thereof to the Underwriters and dealers; (ii) the cost of printing or producing any
Agreement among Underwriters, this Agreement, the Blue Sky and legal investment memoranda,
closing documents (including any compilations thereof) and any other documents in connection
with the offering, purchase, sale and delivery of the Securities; (iii) all expenses in
connection with the qualification of the Securities for offering and sale under state
securities laws as provided in Section 5(b) hereof, including the fees and disbursements of
counsel for the Underwriters in
9
connection with such qualification and in connection with the Blue Sky and legal
investment surveys; (iv) any fees charged by securities rating services for rating the
Securities; (v) the cost of preparing the Securities; (vi) the fees and expenses of the
Trustee, any agent of the Trustee, including the fees and expenses of the Trustee’s counsel,
any transfer agent, registrar or depositary; (vii) the costs and expenses of the Company
relating to investor presentations on any “road show” undertaken in connection with the
marketing of the offering of the Securities, including, without limitation, expenses
associated with the production of road show slides and graphics, fees and expenses of any
consultants engaged in connection with the road show presentations with the prior approval
of the Company, travel and lodging expenses of the representatives and officers of the
Company and any such consultants, and the cost of any aircraft chartered in connection with
the road show, and all other costs and expenses incident to the performance of its
obligations hereunder which are not otherwise specifically provided for in this Section. It
is understood, however, that, except as provided in this Section and Sections 7 and 9
hereof, the Underwriters will pay all of their own costs and expenses, including the fees of
their counsel, transfer taxes on resale of any of the Securities by them, and any
advertising expenses connected with any offers they may make.
(h) To make generally available to the Company’s security holders and to you as soon as
practicable an earning statement covering the twelve-month period ending June 30, 2009 that
satisfies the provisions of Section 11(a) of the Securities Act and the rules and
regulations of the Commission thereunder.
6. Conditions to the Underwriters’ Obligations. The obligations of the Underwriters
hereunder shall be subject, in their discretion, to the condition that all representations and
warranties and other statements of the Company herein are, at and as of the Closing Date, true and
correct, the condition that the Company shall have performed all of its obligations hereunder
theretofore to be performed, and the following additional conditions:
(a) (1) The Underwriters shall have received on the Closing Date an opinion of Xxxxx
Xxxx & Xxxxxxxx LLP, counsel for the Underwriters, dated the Closing Date, covering the
matters referred to in Sections 6(b)(1)(iii), 6(b)(1)(iv), 6(b)(1)(v), 6(b)(1)(viii)(A) (but
only as to the statements under the captions “Underwriting” and “Description of Notes” and
“Description of Debt Securities”) and 6(b)(1)(x) below, as well as such other related
matters as you may reasonably request, and such counsel shall have received such papers and
information as they may reasonably request to enable them to pass upon such matters; (2) the
Underwriters shall have received on the Closing Date a letter of Xxxxx Xxxx & Xxxxxxxx LLP,
counsel for the Underwriters, dated the Closing Date covering the matters referred to in
Section 6(b)(2) below, but as to clause (i) only as to the Registration Statement as of the
date of this Agreement.
(b) (1) The Underwriters shall have received on the Closing Date an opinion of Milbank,
Tweed, Xxxxxx & XxXxxx LLP, outside counsel for the Company, dated the Closing Date, to the
effect that:
(i) the Company is validly existing as a corporation in good standing under the
laws of the State of New York, with corporate power and authority to
10
own or lease, as the case may be, and to operate its properties and to conduct
its business as described in the Time of Sale Prospectus and the Prospectus;
(ii) each Material Subsidiary of the Company organized in the States of
Delaware or New York and named in Schedule IV hereto is validly existing as
a corporation in good standing under the laws of the jurisdiction of its
incorporation, with corporate power and authority to own or lease, as the case may
be, and to operate its properties and to conduct its business as described in the
Time of Sale Prospectus and the Prospectus;
(iii) this Agreement has been duly authorized, executed and delivered by the
Company;
(iv) the Securities have been duly authorized by the Company and, when
authenticated by the Trustee under the Indenture and executed, delivered and paid
for in accordance with the terms of this Agreement, will be legal, valid and binding
obligations of the Company, enforceable in accordance with their terms, except in
each case: (a) as the enforceability thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or transfer, or
similar laws relating to or affecting creditors’ rights generally and (b) as the
enforceability thereof is subject to the application of general principles of equity
(regardless of whether considered in a proceeding in equity or at law) including (i)
the possible unavailability of specific performance, injunctive relief or any other
equitable remedy and (ii) concepts of materiality, reasonableness, good faith and
fair dealing; each registered holder of the Securities will be entitled to the
benefits of the Indenture;
(v) the Indenture has been duly authorized, executed and delivered by the
Company and constitutes a legal, valid and binding agreement of the Company,
enforceable against it in accordance with its terms, except (a) as the
enforceability thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or transfer, or similar laws relating to or
affecting creditors’ rights generally and (b) as the enforceability thereof is
subject to the application of general principles of equity (regardless of whether
considered in a proceeding in equity or at law) including (i) the possible
unavailability of specific performance, injunctive relief or any other equitable
remedy; and (ii) concepts of materiality, reasonableness, good faith and fair
dealing; and (c) in the case of rights to indemnity as may be limited by provisions
imposed by law or public policy; the Indenture has been duly qualified under the
Trust Indenture Act.
(vi) neither the execution and delivery by the Company of this Agreement nor
the sale of the Securities by the Company thereunder will (i) result in a breach or
violation of the restated certificate of incorporation or by-laws of the Company,
each as amended, or (ii) constitute a breach or violation of, or a default under or
result in the imposition of any lien, charge or encumbrance upon any property or
assets of the Company pursuant to any applicable law, provided
11
that such counsel expresses no opinion as to the indemnification provisions
contained therein may be considered under applicable law to contravene public
policy;
(vii) no consent, authorization, approval or order of, or registration,
qualification or filing with, any United States federal or State of New York
administrative, judicial or other governmental agency, authority, tribunal or body
is required on the part of the Company for the execution and delivery by the Company
of this Agreement or the Indenture or the consummation of the sale of the Securities
by the Company thereunder, except such as have been made or obtained prior to the
date hereof or as may be required under state securities or “blue sky” laws of any
jurisdiction, as to which such counsel expresses no opinion;
(viii) the statements set forth (A) in the Time of Sale Prospectus and the
Prospectus under the caption “Description of Debt Securities”, “Description of
Notes” and, subject to the limitations and qualifications stated therein, “Certain
U.S. Federal Tax Considerations for Non-U.S. Holders” and (B) in the Registration
Statement in Item 15, in each case to the extent that they purport to summarize
provisions of certain agreements or documents referred to therein or U.S. federal
income tax matters, fairly summarize in all material respects such provisions of
such agreements, documents or matters;
(ix) the Company is not required to, and, immediately after giving effect to
the offering and sale of the Securities and the application of the proceeds thereof
as described in the Prospectus, the Company will not be required to, register as an
investment company under the Investment Company Act of 1940, as amended;
(x) the Registration Statement, as of its effective date (including each deemed
effective date pursuant to Rule 430B(f)(2)), and as of the date of this Agreement
and the Prospectus, as of the date thereof (except any financial statements or other
financial data included in or omitted from, or incorporated by reference in, the
Registration Statement or the Prospectus, as to which no opinion is expressed)
appear on their face to be appropriately responsive, in all material respects
relevant to the offering of the Securities, to the requirements of the Securities
Act and the Exchange Act, as applicable, and the applicable rules and regulations of
the Commission thereunder; in rendering this opinion, such counsel need not take
responsibility for the accuracy, completeness or fairness of the statements made in
the Registration Statement or the Prospectus, except to the extent set forth in
paragraph (viii);
(2) The Underwriters shall have received on the Closing Date a letter of Milbank,
Tweed, Xxxxxx & XxXxxx LLP, outside counsel for the Company, dated the Closing Date to the
effect that nothing has come to such counsel’s attention that causes it to believe that:
(i) the Registration Statement (other than the financial statements and schedules and other
financial and accounting information and data, management’s report
12
on the effectiveness of internal control over financial reporting, and that part of the
Registration Statement that constitutes the Form T-1, as to which such counsel expresses no
belief and makes no statement), as of the effective date of the Registration Statement
(including each deemed effective date pursuant to Rule 430B(f)(2)) or as of the date of this
Agreement, contained an untrue statement of a material fact or omitted to state any material
fact required to be stated therein or necessary to make the statements therein not
misleading; (ii) the Time of Sale Prospectus (other than the financial statements and other
financial and accounting information and data and management’s report on the effectiveness
of internal control over financial reporting, as to which such counsel expresses no belief
and makes no statement), as of the Time of Sale, contained an untrue statement of a material
fact or omitted to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; or (iii) the
Prospectus (other than the financial statements and other financial and accounting
information and data and management’s report on the effectiveness of internal control over
financial reporting, as to which such counsel expresses no belief and makes no statement),
as of its date or as of the Closing Date, contained or contains an untrue statement of a
material fact or omitted or omits to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not
misleading.
With respect to the foregoing paragraph, such counsel may state that they reviewed the
Registration Statement, the Time of Sale Prospectus, the Prospectus and each free writing
prospectus identified in Schedule II to this Agreement, they reviewed certain
corporate records and documents furnished to them by the Company and they participated in
discussions with representatives of the Company, independent registered public accountants
for the Company and your representatives regarding the Registration Statement, the Time of
Sale Prospectus, the Prospectus and each such free writing prospectus and related matters.
The purpose of their professional engagement was not to establish or confirm factual matters
set forth in the Registration Statement, the Time of Sale Prospectus or the Prospectus, and
they have not undertaken to verify independently any of such factual matters. Moreover,
many of the determinations required to be made in the preparation of the Registration
Statement, the Time of Sale Prospectus and the Prospectus involve matters of a non-legal
nature. Accordingly, they are not passing upon and do not assume any responsibility for the
accuracy, completeness or fairness of the statements contained in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, and they make no representation
that they have independently verified the accuracy, completeness or fairness of such
statements except to the extent set forth in paragraph (b)(viii). In addition, they are not
passing upon and do not assume any responsibility for ascertaining whether or when any of
the Time of Sale Prospectus or the Prospectus was conveyed to any person for purposes of
Rule 159 under the Securities Act.
(c) The Underwriters shall have received on the Closing Date an opinion of Xxxxx X.
Xxxxx, Senior Vice President and General Counsel of the Company, dated the Closing Date, in
form and substance satisfactory to the Underwriters, to the effect that:
13
(i) such counsel is of the opinion that each document, if any, filed pursuant
to the Exchange Act and incorporated by reference in the Time of Sale Prospectus or
the Prospectus (other than the financial statements or other financial data and
schedules included therein as to which such counsel need not express any opinion)
complied when so filed as to form in all material respects with the Exchange Act and
the rules and regulations of the Commission thereunder;
(ii) to the best of such counsel’s knowledge, (x) there are no legal or
governmental proceedings pending to which the Company or any of its subsidiaries is
a party or to which any of the properties of the Company or any of its subsidiaries
is subject other than as described in the Time of Sale Prospectus or the Prospectus
and other than such legal or governmental proceedings which individually or in the
aggregate are not material to the Company and its subsidiaries taken as a whole and
no such proceedings are threatened by others, and (y) there are no statutes,
regulations, contracts or other documents that are required to be described in the
Time of Sale Prospectus or the Prospectus or to be filed or incorporated by
reference as exhibits to the Registration Statement that are not described, filed,
or incorporated as required; and
(iii) neither the execution and delivery by the Company of this Agreement, nor
the sale of the Securities by the Company hereunder, results in a breach or
violation of any agreement or other instrument known to such counsel binding upon
the Company or any of its Material Subsidiaries or to which any of its or their
properties are subject (including, without limitation, any credit agreement,
indenture or other financing agreement) that is material to the Company and its
subsidiaries, taken as a whole, or, to the best of such counsel’s knowledge, any
judgment, order or decree that is material to the Company and its subsidiaries taken
as a whole, of any governmental body, agency or court having jurisdiction over the
Company or any subsidiaries or any of their properties.
(d) On each of the date hereof and the Closing Date, Ernst & Young LLP, independent
public accountants, shall have furnished to you a letter or letters, dated the respective
dates of delivery thereof, in form and substance satisfactory to you containing statements
and information of the type ordinarily included in accountants’ “comfort letters” to
underwriters with respect to the financial statements and certain financial information
contained or incorporated by reference into the Registration Statement, the Time of Sale
Prospectus and the Prospectus; provided that the letter delivered on the Closing Date shall
use a “cut-off date” not earlier than the date hereof.
(e) Since the date of this Agreement, or if earlier, the respective dates as of which
information is given in the Time of Sale Prospectus there shall not have been any change in
the capital stock or long-term debt of the Company or any of its subsidiaries or any change,
or any development involving a prospective change, in or affecting the general affairs,
management, financial position, shareholders’ equity or results of operations of the Company
and its subsidiaries, otherwise than as set forth or contemplated in the Time of Sale
Prospectus, the effect of which, in any such case described in this paragraph, is in the
judgment of the Underwriters so material and
14
adverse as to make it impracticable or inadvisable to proceed with the offering or the
delivery of the Securities on the terms and in the manner contemplated in this Agreement and
in the Time of Sale Prospectus and the Prospectus.
(f) On or after the date hereof (i) no downgrading shall have occurred in the rating
accorded the Company’s debt securities by any “nationally recognized statistical rating
organization”, as that term is defined by the Commission for purposes of Rule 436(g)(2)
under the Act, and (ii) no such organization shall have publicly announced that it has under
surveillance or review, with possible negative implications, its rating of any of the
Company’s debt securities.
(g) The Company shall have furnished or caused to be furnished to you at the Closing
Date a certificate of Xxxx X. Xxxxxx, Senior Vice President and Chief Financial Officer of
the Company, satisfactory to you as to the accuracy of the representations and warranties of
the Company herein at and as of such Closing Date, as to the performance by the Company of
all of its obligations hereunder to be performed at or prior to such Closing Date, as to the
matters set forth in subsection 6(e) and as to such other matters as you may reasonably
request.
7. Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless each
Underwriter and each person, if any, who controls any Underwriter within the meaning of either
Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of any
underwriter within the meaning of Rule 405 of the Securities Act from and against any and all
losses, claims, damages and liabilities (including, without limitation, any legal or other
expenses reasonably incurred in connection with defending or investigating any such action or
claim) caused by any untrue statement or alleged untrue statement of a material fact contained in
the Registration Statement or any amendment thereto, any preliminary prospectus, the Time of Sale
Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act,
any Company information that the Company has filed, or is required to file, pursuant to Rule
433(d) (including each free writing prospectus listed on Schedule II) under the
Securities Act or the Prospectus (or any amendments or supplements thereto if the Company shall
have furnished any amendments or supplements thereto), or caused by any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, except insofar as such losses, claims, damages or liabilities
are caused by any such untrue statement or omission or alleged untrue statement or omission based
upon information relating to any Underwriter furnished to the Company in writing by such
Underwriter through you expressly for use therein.
(b) Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, its directors, its officers who sign the Registration Statement and each person, if any,
who controls the Company within the meaning of either Section 15 of the Securities Act or Section
20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such
Underwriter, but only with reference to information relating to such Underwriter furnished to the
Company in writing by such Underwriter through you expressly for use in the Registration Statement,
any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the
Prospectus or any amendments or supplements thereto.
15
(c) In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section 7(a) or 7(b),
such person (the “indemnified party”) shall promptly notify the person against whom such indemnity
may be sought (the “indemnifying party”) in writing and the indemnifying party, upon request of the
indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to
represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In
any such proceeding, any indemnified party shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the
indemnifying party and the indemnified party shall have mutually agreed to the retention of such
counsel or (ii) the named parties to any such proceeding (including any impleaded parties) include
both the indemnifying party and the indemnified party and representation of both parties by the
same counsel would be inappropriate due to actual or potential differing interests between them.
It is understood that the indemnifying party shall not, in respect of the legal expenses of any
indemnified party in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
any local counsel) for all such indemnified parties and that all such fees and expenses shall be
reimbursed as they are incurred. Such firm shall be designated in writing by Banc of America
Securities LLC, Xxxxxxx, Sachs & Co. and X.X. Xxxxxx Securities Inc., in the case of parties
indemnified pursuant to Section 7(a), and by the Company, in the case of parties indemnified
pursuant to Section 7(b). The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a
final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party
from and against any loss or liability by reason of such settlement or judgment. No indemnifying
party shall, without the prior written consent of the indemnified party, effect any settlement of
any pending or threatened proceeding in respect of which any indemnified party is or could have
been a party and indemnity could have been sought hereunder by such indemnified party, unless such
settlement includes an unconditional release of such indemnified party from all liability on claims
that are the subject matter of such proceeding.
(d) To the extent the indemnification provided for in Section 7(a) or 7(b) is unavailable to
an indemnified party or insufficient in respect of any losses, claims, damages or liabilities
referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying
such indemnified party thereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion
as is appropriate to reflect the relative benefits received by the Company on the one hand and the
Underwriters on the other hand from the offering of the Securities or (ii) if the allocation
provided by clause 7(d)(i) above is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause 7(d)(i) above but also
the relative fault of the Company on the one hand and of the Underwriters on the other hand in
connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative benefits
received by the Company on the one hand and the Underwriters on the other hand in connection with
the offering of the Securities shall be deemed to be in the same respective proportions as the net
proceeds from the offering of the Securities (before deducting expenses) received by the Company
and the total underwriting discounts and commissions received by the Underwriters, in
16
each case as set forth in the table on the cover of the Prospectus, bear to the aggregate
public offering price of the Securities. The relative fault of the Company on the one hand and the
Underwriters on the other hand shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or by the Underwriters and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission. The Underwriters’ respective obligations to contribute pursuant to
this Section 7 are several in proportion to the respective principal amounts of Securities they
have purchased hereunder, and not joint.
(e) The Company and the Underwriters agree that it would not be just or equitable if
contribution pursuant to this Section 7 were determined by pro rata allocation (even if the
Underwriters were treated as one entity for such purpose) or by any other method of allocation that
does not take account of the equitable considerations referred to in Section 7(d). The amount paid
or payable by an indemnified party as a result of the losses, claims, damages and liabilities
referred to in the immediately preceding paragraph shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this Section 7, no Underwriter shall be required to contribute any amount in excess
of the amount by which the total price at which the Securities underwritten by it and distributed
to the public were offered to the public exceeds the amount of any damages that such Underwriter
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The remedies provided for in this Section 7 are not
exclusive and shall not limit any rights or remedies which may otherwise be available to any
indemnified party at law or in equity.
(f) The indemnity and contribution provisions contained in this Section 7 and the
representations, warranties and other statements of the Company contained in this Agreement shall
remain operative and in full force and effect regardless of (i) any termination of this Agreement,
(ii) any investigation made by or on behalf of any Underwriter or any person controlling any
Underwriter or any affiliate of any Underwriter or by or on behalf of the Company, its officers or
directors or any person controlling the Company and (iii) acceptance of and payment for any of the
Securities.
8. Termination. This Agreement shall be subject to termination at your discretion by notice
given by you to the Company, if (a) after the execution and delivery of this Agreement and prior
to the Closing Date (i) trading generally shall have been suspended or materially limited on or
by, as the case may be, any of the New York Stock Exchange, the American Stock Exchange, the
Nasdaq Stock Market LLC, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange,
the Chicago Board of Trade or any over-the-counter market, (ii) trading of any securities issued
or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter
market, (iii) a general moratorium on commercial banking activities shall have been declared by
either Federal or New York State authorities or a material disruption in commercial banking or
securities settlement or clearance services in the United States shall have occurred; or (iv)
there shall have occurred any outbreak
17
or escalation of hostilities or any change in financial markets or any calamity or crisis,
either within or outside the United States, that, in your judgment, is material and adverse and
(b) in the case of any event specified in clauses 8(a)(i) through 8(a)(iv), such event, singly or
together with any other such event, makes it, in your judgment, impracticable or inadvisable to
proceed with the offering, sale or delivery of the Securities on the terms and in the manner
contemplated in this Agreement, the Time of Sale Prospectus or the Prospectus.
9. Effectiveness; Defaulting Underwriters. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.
If, on the Closing Date any one or more of the Underwriters shall fail or refuse to purchase
Securities that it has or they have agreed to purchase hereunder on such date, and the aggregate
principal amount at maturity of Securities which such defaulting Underwriter or Underwriters agreed
but failed or refused to purchase is not more than one-tenth of the aggregate principal amount at
maturity of the Securities to be purchased on such date, the other Underwriters shall be obligated
severally in the proportions that the aggregate principal amount at maturity of Securities set
forth opposite their respective names in Schedule I bears to the aggregate principal amount
at maturity of Securities set forth opposite the names of all such non-defaulting Underwriters, or
in such other proportions as you may specify, to purchase the Securities which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that in
no event shall the aggregate principal amount at maturity of Securities that any Underwriter has
agreed to purchase pursuant to this Agreement be increased pursuant to this Section 9 by an amount
in excess of one-ninth of such aggregate principal amount at maturity of Securities without the
written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Securities which it or they have agreed to purchase hereunder on
such date and the aggregate principal amount at maturity of Securities with respect to which such
default occurs is more than one-tenth of the aggregate principal amount of Securities to be
purchased on such date, and arrangements satisfactory to you and the Company for the purchase of
such Securities are not made within 36 hours after such default, this Agreement shall terminate
without liability on the part of any non-defaulting Underwriter or the Company. In any such case
either you or the Company shall have the right to postpone the Closing Date, but in no event for
longer than seven days, in order that the required changes, if any, in the Registration Statement,
in the Time of Sale Prospectus and in the Prospectus or in any other documents or arrangements may
be effected. Any action taken under this paragraph shall not relieve any defaulting Underwriter
from liability in respect of any default of such Underwriter under this Agreement.
If this Agreement shall be terminated by the Underwriters, or any of them, because of any
failure or refusal on the part of the Company to comply with the terms or to fulfill any of the
conditions of this Agreement, or if for any reason the Company shall be unable to perform its
obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters
as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket
expenses (including the fees and disbursements of their counsel) reasonably incurred by such
Underwriters in connection with this Agreement or the offering contemplated hereunder.
18
10. Entire Agreement. This Agreement, together with any contemporaneous written agreements and
any prior written agreements (to the extent not superseded by this Agreement) that relate to the
offering of the Securities, represents the entire agreement between the Company and the
Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale
Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the
Securities.
11. Notices. In all dealings hereunder, you shall act on behalf of each of the Underwriters,
and the parties hereto shall be entitled to act and rely upon any statement, request, notice or
agreement on behalf of any Underwriter made or given by you on their behalf.
All statements, requests, notices and agreements hereunder shall be in writing and, if to the
Underwriters, shall be delivered or sent by mail, telex or facsimile transmission to you as the
representatives in care of Banc of America Securities LLC, 00 Xxxx 00xx Xxxxxx, Xxx
Xxxx, Xxx Xxxx 00000, Attention: High Grade Capital Markets Transaction Management; fax (000)
000-0000; X.X. Xxxxxx Securities Inc. 000 Xxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx, attention: Investment
Grade Syndicate Desk; fax (000) 000-0000; Xxxxxxx, Sachs & Co., 00 Xxxxx Xxxxxx, 00xx
Xxxxx, Xxx Xxxx, Xxx Xxxx, 00000, Attention: Registration Department; fax (000) 000-0000; and, if
to the Company, shall be delivered or sent by mail, telex or facsimile transmission to the address
of the Company set forth in the Prospectus, Attention: Secretary.
12. Binding Effect. This Agreement shall be binding upon, and inure solely to the benefit
of, the Underwriters, the Company and, to the extent provided in Section 7 hereof, the officers
and directors of the Company, each person who controls the Company or any Underwriter, each
affiliate of any Underwriter and their respective heirs, executors, administrators, successors and
assigns, and no other person shall acquire or have any right under or by virtue of this Agreement.
No purchaser of any of the Securities from any Underwriter shall be deemed a successor or assign
by reason merely of such purchase.
13. Absence of Fiduciary Relationship. The Company acknowledges that in connection with the
offering of the Securities: (i) the Underwriters have acted at arms length, are not agents of,
and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the
Company only those duties and obligations set forth in this Agreement and prior written agreements
(to the extent not superseded by this Agreement), if any, and (iii) the Underwriters may have
interests that differ from those of the Company. Additionally, no such Underwriter is advising
the Company or any other person as to any legal, tax, investment, accounting or regulatory matters
in any jurisdiction. The Company shall consult with its own advisors concerning such matters and
shall be responsible for making its own independent investigation and appraisal of the
transactions contemplated herewith. The Company waives to the full extent permitted by applicable
law any claims it may have against the Underwriters arising from an alleged breach of fiduciary
duty in connection with the offering of the Securities.
14. Timing. Time shall be of the essence of this Agreement.
15. Applicable Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of New York.
19
16. Counterparts. This Agreement may be executed by any one or more of the parties hereto in
any number of counterparts, each of which shall be deemed to be an original, but all such
respective counterparts shall together constitute one and the same instrument.
If the foregoing is in accordance with your understanding, please sign and return to us 5
counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters,
this letter and such acceptance hereof shall constitute a binding agreement between each of the
Underwriters and the Company. It is understood that your acceptance of this letter on behalf of
each of the Underwriters is pursuant to the authority set forth in a form of Agreement among
Underwriters, the form of which shall be submitted to the Company for examination upon request, but
without warranty on your part as to the authority of the signers thereof.
17. Headings. The headings of the sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed a part of this Agreement.
20
Very truly yours, ARROW ELECTRONICS, INC. |
||||
By: | /s/ Xxxxxxx X. Xxxxxxx | |||
Name: | Xxxxxxx X. Xxxxxxx | |||
Title: | Vice President & Treasurer | |||
[Signature Page to Underwriting Agreement]
Accepted as of the date hereof Banc of America Securities LLC Xxxxxxx, Xxxxx & Co. X.X. Xxxxxx Securities Inc. Acting severally on behalf of themselves and the several Underwriters named in Schedule I hereto. Banc of America Securities LLC |
||||
By: | /s/ Xxxxxx Xxxxxxxx | |||
Name: | Xxxxxx Xxxxxxxx | |||
Title: | Managing Director | |||
Xxxxxxx, Sachs & Co. |
||||
By: | /s/ Xxxxxxx, Xxxxx & Co. | |||
Xxxxxxx, Sachs & Co. | ||||
X.X. Xxxxxx Securities Inc. |
||||
By: | /s/ Xxxxxxx X. Xxxxxxx | |||
Name: | Xxxxxxx X. Xxxxxxx | |||
Title: | Vice President | |||
[Signature Page to Underwriting Agreement]
SCHEDULE I
Aggregate | ||||
Principal | ||||
Amount of | ||||
Securities to | ||||
Underwriters | be Purchased | |||
Banc of America Securities LLC |
$ | 80,250,000 | ||
X.X. Xxxxxx Securities Inc. |
$ | 80,250,000 | ||
Xxxxxxx, Xxxxx & Co. |
$ | 23,250,000 | ||
Credit Suisse Securities (USA) LLC |
$ | 32,250,000 | ||
Xxxxxx Xxxxxxx & Co. Incorporated |
$ | 32,250,000 | ||
BNP Paribas Securities Corp. |
$ | 17,250,000 | ||
Mitsubishi UFJ Securities (USA), Inc. |
$ | 17,250,000 | ||
Scotia Capital (USA) Inc. |
$ | 17,250,000 | ||
Total |
$ | 300,000,000 | ||
SCHEDULE II
Free Writing Prospectuses
Included in the Time of Sale Prospectus
Included in the Time of Sale Prospectus
1. Pricing term sheet dated September 23, 2009 in the form of Schedule III to the
Underwriting Agreement.
SCHEDULE III
Arrow Electronics, Inc.
Pricing Term Sheet
September 23, 2009
6.000% Notes due April 1, 2020
Issuer:
|
Arrow Electronics, Inc. | |
Principal Amount:
|
$300,000,000 | |
Maturity:
|
April 1, 2020 | |
Coupon:
|
6.000% per annum, accruing from September 30, 2009 | |
Price to Public:
|
99.969% | |
Yield to Maturity:
|
6.004% | |
Spread to Benchmark Treasury:
|
2.500% | |
Benchmark Treasury:
|
3.625% August 15, 2019 | |
Benchmark Treasury Spot and Yield:
|
101-00; 3.504 % | |
Interest Payment Dates:
|
April 1 and October 1, commencing April 1, 2010 | |
Make-Whole Call:
|
Treasury Rate plus 40 basis points | |
Trade Date:
|
September 23, 2009 | |
Settlement Date:
|
September 30, 2009 (T+5) | |
Denominations:
|
$2,000 and higher multiples of $1,000 | |
Ratings:
|
Xxxxx’x: Baa3 / S&P: BBB- / Fitch: BBB- | |
Joint Book-Running Managers:
|
Banc of America Securities LLC X.X. Xxxxxx Securities Inc. Xxxxxxx, Sachs & Co. |
|
Co-Managers:
|
Credit Suisse Securities (USA) LLC Xxxxxx Xxxxxxx & Co. Incorporated BNP Paribas Securities Corp. Mitsubishi UFJ Securities (USA), Inc. Scotia Capital (USA) Inc. |
|
CUSIP/ISIN:
|
000000XX0/US042735BA76 | |
Tender Offer for 9.15% Senior
Notes due 2010:
|
On September 23, 2009, the Company commenced a fixed price cash tender offer (the “tender offer”) for any and all of its outstanding $200 million in aggregate principal amount of 9.15% Senior Notes due 2010 (the “2010 notes”). The consideration for the 2010 notes validly tendered and accepted for payment pursuant to the tender offer is $1,077.50 per $1,000 principal amount of the 2010 notes. In addition, the Company will pay all accrued and unpaid interest on the 2010 notes purchased pursuant to the tender offer up to, but not including, the settlement date for the tender offer. | |
The tender offer is being made on the terms and subject to the conditions set forth in the offer to |
purchase, dated September 23, 2009, relating to the tender offer. The tender offer may not be consummated in accordance with its terms, or at all, so all or a portion of the 2010 notes may remain outstanding. This offering is not conditioned upon the successful consummation of the tender offer. |
Note: A securities rating is not a recommendation to buy, sell or hold securities and may be
subject to revision or withdrawal at any time.
The issuer has filed a registration statement (including a prospectus) with the SEC for the
offering to which this communication relates. Before you invest, you should read the prospectus in
that registration statement and other documents the issuer has filed with the SEC for more complete
information about the issuer and this offering. You may get these documents for free by visiting
XXXXX on the SEC web site at xxx.xxx.xxx. Alternatively, the issuer, any underwriter or any dealer
participating in the offering will arrange to send you the prospectus if you request it by calling
Banc of America Securities LLC toll free at 1-800-294-1322, X.X. Xxxxxx Securities Inc. collect at
000-000-0000 or Xxxxxxx, Sachs & Co. at Prospectus Department, 00 Xxxxx Xxxxxx, Xxx Xxxx, XX 00000,
telephone: 0-000-000-0000, facsimile: 000-000-0000 or by emailing xxxxxxxxxx-xx@xx.xxxxx.xx.xxx.
Any disclaimer or other notice that may appear below is not applicable to this communication and
should be disregarded. Such disclaimer or notice was automatically generated as a result of this
communication being sent by Bloomberg or another email system.
SCHEDULE IV
List of Material Subsidiaries pursuant to Section 6(b)(1)(ii)
Arrow Electronics (U.K.), Inc.
Arrow Enterprise Computing Solutions, Inc.